Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease

Journal of Neural Transmission
Angelo Antonini, Bianca Nitu

Abstract

Development of motor fluctuations and dyskinesia characterizes the transition from early to advanced Parkinson disease stage. Current therapeutic strategies to manage motor complications aim at increasing the number of levodopa administrations and extending its benefit by the association of enzyme blockers and dopamine agonists. However, as disease progresses, mobility becomes progressively dependent on levodopa absorption and its plasma bioavailability, resulting in loss of independence, worse quality of life and increased caregiver burden. If patients continue to experience off-time with functional impact on activities of daily living after best medication adjustments, implementation of infusion with apomorphine or levodopa, and surgical therapies should be considered. Presence of troublesome dyskinesia would also favor the choice of an advanced treatment. Compared with pulsatile oral therapy, both apomorphine and levodopa infusion determine more continuous striatal dopamine receptors stimulation than oral levodopa resulting in significant reduction of off-time and dyskinesia, particularly peak-dose, although not in their complete resolution. This observation proves that abnormal synaptic plasticity and connectivity changes c...Continue Reading

References

Oct 6, 2000·Clinical Neuropharmacology·A Hadj TaharP J Bédard
Aug 17, 2002·Brain : a Journal of Neurology·Fabrizio StocchiC Warren Olanow
Sep 25, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Regina KatzenschlagerAndrew J Lees
Dec 14, 2004·The New England Journal of Medicine·Stanley FahnUNKNOWN Parkinson Study Group
Mar 22, 2008·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·J C SharmaD Brooks
Jun 6, 2009·Expert Review of Neurotherapeutics·Angelo Antonini, Eduardo Tolosa
Nov 2, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Susan H FoxCristina Sampaio
Jul 11, 2012·Nature Reviews. Neurology·Miguel Coelho, Joaquim J Ferreira
Nov 13, 2012·Movement Disorders : Official Journal of the Movement Disorder Society·Erwan Bezard
Feb 15, 2013·The New England Journal of Medicine·W M M SchuepbachUNKNOWN EARLYSTIM Study Group
Jan 17, 2014·Scientific Reports·Gregory PorrasWassilios G Meissner
Nov 11, 2014·Movement Disorders : Official Journal of the Movement Disorder Society·Pablo Martinez-MartinK Ray Chaudhuri
Dec 9, 2014·Expert Opinion on Drug Safety·Manuela Pilleri, Angelo Antonini
Sep 12, 2015·Acta Neurologica Scandinavica·J TimpkaK Ray Chaudhuri
Nov 21, 2015·Parkinsonism & Related Disorders·Anders BjornestadGuido Alves
Dec 24, 2015·Movement Disorders : Official Journal of the Movement Disorder Society·Anthony E LangJordan Dubow
Dec 29, 2015·Parkinsonism & Related Disorders·Robbert W K BorgemeesterTeus van Laar
Jan 29, 2016·Movement Disorders : Official Journal of the Movement Disorder Society·Angelo AntoniniJanet A Benesh
Dec 17, 2016·Parkinsonism & Related Disorders·Peter Jenner, Regina Katzenschlager
Feb 28, 2017·Parkinsonism & Related Disorders·Mariachiara SensiUNKNOWN ITALIAN LEVODOPA CARBIDOPA INTESTINAL GEL WORKING GROUP
Apr 9, 2017·Parkinsonism & Related Disorders·Margherita FabbriJoaquim J Ferreira
May 31, 2017·International Review of Neurobiology·Jonathan TimpkaAngelo Antonini
Oct 19, 2017·Parkinsonism & Related Disorders·Angelo AntoniniUNKNOWN GLORIA study co-investigators
Oct 27, 2017·Frontiers in Aging Neuroscience·Arianna BellucciPierFranco Spano
Dec 22, 2017·Neuromodulation : Journal of the International Neuromodulation Society·Haidar Salimi DafsariUNKNOWN EUROPAR and the IPMDS Non-Motor PD Study Group
Mar 1, 2018·Movement Disorders : Official Journal of the Movement Disorder Society·M Angela Cenci, Alan R Crossman
Mar 23, 2018·Neurodegenerative Disease Management·Mazen T ElkurdRajesh Pahwa
Mar 24, 2018·Movement Disorders : Official Journal of the Movement Disorder Society·Angelo AntoniniHeinz Reichmann
Jun 15, 2018·Neurology·Laura Y CabreraChristos Sidiropoulos

❮ Previous
Next ❯

Citations

Jul 6, 2020·Fortschritte der Neurologie-Psychiatrie·Gerhard Ransmayr
Jul 7, 2020·Fortschritte der Neurologie-Psychiatrie
Oct 16, 2018·Drugs & Aging·Margherita FabbriJoaquim J Ferreira
Dec 26, 2018·Journal of Parkinson's Disease·Daniel J van WamelenPer Odin
May 7, 2019·Expert Opinion on Pharmacotherapy·Thomas MüllerJan-Dominique Möhr
Jul 12, 2020·Journal of Parkinson's Disease·Joke M DijkRob M A de Bie
Jul 7, 2020·Movement Disorders Clinical Practice·Tomi KuusimäkiValtteri Kaasinen
Aug 8, 2020·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Stephen D Aradi, Robert A Hauser
Nov 17, 2020·Frontiers in Cellular and Infection Microbiology·Jing LiuLei Shao
Dec 10, 2020·Neuropsychiatric Disease and Treatment·Nicola ModugnoLeonardo Lopiano
Apr 27, 2021·Movement Disorders : Official Journal of the Movement Disorder Society·Taiji TsunemiNobutaka Hattori
Jul 27, 2021·Movement Disorders Clinical Practice·Iro BouraCleanthe Spanaki
Dec 18, 2021·Neurodegenerative Disease Management·Thomas Müller

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Movement Disorders : Official Journal of the Movement Disorder Society
Angelo AntoniniHeinz Reichmann
Parkinsonism & Related Disorders
Daniela Calandrella, Angelo Antonini
© 2022 Meta ULC. All rights reserved